Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection by Beers, Stephen A. et al.
 1
TITLE: Antigenic modulation limits the efficacy of anti-CD20 antibodies: 
implications for antibody selection 
 
Running title: Rituximab modulates CD20 from the B-cell surface  
 
Stephen A Beers1§, Ruth R French1§, Claude HT Chan1, Sean H Lim1, Timothy C Jarrett1, 
Regina Mora Vidal1, Sahan S Wijayaweera1, Sandra V Dixon1, Hyung J Kim1, Kerry L 
Cox1, Jonathan P Kerr1, David A Johnston2, Peter W M Johnson3, Sjef Verbeek4, Martin 
J Glennie1# and Mark S Cragg1# 
  
From: 1Tenovus Laboratory, Cancer Sciences Division, Southampton University School 
of Medicine, General Hospital, Southampton, SO16 6YD, UK. 2Biomedical Imaging 
Unit, Southampton University School of Medicine, General Hospital, Southampton, 
SO16 6YD, UK. 3Cancer Research UK Cancer Centre, Southampton University School 
of Medicine, General Hospital, Southampton, SO16 6YD, UK. 4Department of Human 
Genetics, Leiden University Medical Centre, Leiden, The Netherlands. 
 
§
 These authors contributed equally to the project and should both be considered first 
authors. # These authors are the senior authors and contributed equally to the study. 
 
 
 
 Blood First Edition Paper, prepublished online March 16, 2010; DOI 10.1182/blood-2010-01-263533
 Copyright © 2010 American Society of Hematology
 2
Address correspondence and reprint requests: Mark S Cragg, Tenovus Laboratory, Cancer 
Sciences Division, Southampton University School of Medicine, General Hospital, 
Southampton, SO16 6YD, UK (FAX: +44 (0) 23 80777222 8056; e-mail: 
msc@soton.ac.uk) 
 
Scientific Heading: Immunobiology 
 
 
 3
Abstract 
Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the 
treatment of a variety of malignant and autoimmune disorders. Despite this success a 
substantial proportion of B-cell lymphomas are unresponsive or develop resistance, hence 
more potent anti-CD20 mAb are continually being sought. Here we demonstrate that type 
II (tositumomab-like) anti-CD20 mAb are 5 times more potent than type I (rituximab-
like) reagents in depleting human CD20 Tg B-cells, despite both operating exclusively 
via activatory FcR-expressing macrophages.  Much of this disparity in performance is 
attributable to type I mAb-mediated internalization of CD20 by B-cells leading to 
reduced macrophage recruitment and the degradation of CD20:mAb complexes, 
shortening mAb half-life. Importantly, human B cells from healthy donors, and most 
cases of Chronic Lymphatic Leukemia (CLL) and Mantle Cell Lymphoma, showed rapid 
CD20 internalization which paralleled that seen in the Tg mouse B cells, while most 
Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) cells were far 
more resistant to CD20 loss. We postulate that differences in CD20 modulation may play 
a central role in determining the relative efficacy of rituximab in treating these diseases 
and strengthen the case for focusing on type II anti-CD20 mAb in the clinic. 
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Introduction 
The antibody rituximab is widely used in the treatment of B-cell diseases, and many 
second and third generation anti-CD20 monoclonal antibodies (mAb) are currently 
undergoing clinical development 1. Persistent lack of clarity regarding the precise mode 
of action for anti-CD20 mAb is reflected in the variety of approaches being taken to 
improve the potency of these reagents 2. While it is widely accepted that Fc:Fc γ receptor 
(FcγR) interactions are vital 3, 4, the importance of the two other potential effector 
pathways, complement-dependent cytotoxicity (CDC) and programmed cell death (PCD), 
is still disputed 5. We have previously described two classes of anti-CD20 mAb, based 
upon differences in their engagement of the antigen; type I (rituximab-like) and type II 
(tositumomab-like). Type I mAb are able to redistribute CD20 into lipid rafts and evoke 
complement activation, whereas type II induce homotypic adhesion and non-apoptotic 
cell death 6-8.  Interestingly, type I and II reagents cannot be distinguished by the region 
of CD20 they engage, since almost all anti-CD20 mAb share small, closely overlapping 
epitopes which focus on an Alanine x Proline motif identified by Deans and colleagues 9, 
10
.  It seems more likely that it is the orientation of binding and the degree of CD20 cross-
linking which determine their type and nature. 
 
The efficacy of rituximab in lymphoma therapy varies according to tumor burden 11, 12 
and sub-type.  Although FL are relatively sensitive, B-CLL and Small Lymphocytic 
Lymphoma (SLL) are significantly less so 13, such that dose escalation with 
approximately 6 times more mAb is required for significant clinical activity 14, 15. 
Although the second generation type I anti-CD20 mAb ofatumumab appears promising 
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16-18
, large (2 g) quantities of mAb are being administered in these trials.  The lower level 
of CD20 expression on CLL is put forward as a possible explanation 19 although 
intuitively this might be expected to consume less mAb. Similarly, it has been suggested 
that soluble CD20 might consume rituximab in CLL 20, but this result has not been 
confirmed and seems unlikely given the hydrophobic nature of CD20 which, with a 
predicted tetraspan structure, is unlikely to persist as a soluble, antigenically intact 
molecule. Some reports have also suggested that modulation of CD20 occurs on CLL and 
NHL lines but these data have been largely unconfirmed with little indication in the 
literature to suggest that this is an important mechanism which impedes efficacy 21, 22.  
We now show that modulation is potentially a key factor in determining the potency of 
CD20 mAb against certain B-cell targets and propose that type II reagents which avoid 
internalization are likely to be more effective drugs for deleting autoimmune and 
malignant B-cells in various disorders. 
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Material and Methods 
Animals and cells  
Mice were bred and maintained in local facilities. hCD20 Tg mice have been described 
previously 1.  Other genetically altered strains used were: γ chain -/-, C1q -/-, C3 -/- 
(Jax® Mice, USA), Vav-Bcl-2 Tg.  hCD20 Tg x γ chain -/- and  Vav-Bcl-2 x hCD20 Tg 
mice were obtained by crossbreeding, with genotypes confirmed by PCR and/or flow 
cytometry. Animal experiments were cleared through local ethical committee and were 
performed under Home Office licence PPL30/1269. Human cell-lines were obtained from 
ECACC (Daudi, Raji, Ramos, SU-DHL-4), were a kind gift from Dr J Teeling (Granta 
519) or Dr L Nolan (DOHH-2, HBL-1, RL) and were maintained in antibiotic-free media. 
Mouse splenic B-cells and normal human peripheral B-cells were purified by negative 
selection using MACS B-cell isolation kits (Miltenyi Biotec).  
 
Antibodies and reagents 
All mAb have previously been described 1 except for FGM6, which is a novel type II 
anti-CD20 mAb constructed from patented published sequences with additional 
mutations. MAb were produced in either the 293F Freestyle system (Invitrogen) or CHO-
K1. IgG was purified on Protein A with purity assessed by electrophoresis (Beckman EP 
system; Beckman) and lack of aggregation by HPLC. F(ab’)2 fragments were produced as 
described previously 23. Antibodies used for Western blotting were anti-CD20 
(7D1)(AbDSerotec), anti-actin (Sigma) and anti-Alexa 488 (Invitrogen). Clodronate 
(Sigma) or PBS containing liposomes were produced as detailed by van Rooijen and 
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Sanders 24. The actin inhibitor Latrunculin B was from Calbiochem and azide, etoposide 
and dexamethasone from Sigma.  
 
Flow cytometry 
Fluorescently conjugated mAb were from BD Biosciences, AbDSerotec or made in-
house. Flow cytometry was as described previously 25 with samples assessed on a 
FACScan, FACSCalibur or FACSCanto II with data analyzed with CellQuest Pro or 
FACSDiva (all BD Biosciences). To assay anti-CD20 mAb (mouse IgG2 subclass) 
concentrations, sera were incubated with human SU-DHL-4 cells (hCD20+), and cell-
bound anti-CD20 detected using FITC-labeled goat anti-mouse Fc (Jackson 
Immunoresearch) with reference to a standard curve. To determine surface expression of 
CD20 after mAb treatment in vivo or in vitro, available antigen was saturated with excess 
anti-CD20 mAb (10 μg/ml), cells washed and then surface anti-CD20 detected using 
RPE-labeled goat anti-mouse Fc (Jackson Immunoresearch); B-cells were then identified 
with APC-labeled anti-mouse CD19. FACS staining of Bcl-2 levels in hCD20 Tg B cells 
was performed with FITC-labeled anti-Bcl-2 (BD Biosciences) according to the 
manufacturer’s instructions. 
 
B-cell depletion experiments 
hCD20 Tg mice received a single intravenous (i.v.) dose of mAb and B cells remaining in 
the blood or organs assessed by flow cytometry or immunohistochemistry (IHC) 1. 
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Residual B cells were plotted as percentage of B cells in mice treated with irrelevant 
isotype matched mAb (WR17) or PBS. In adoptive transfer experiments, splenocytes 
from hCD20 Tg and wild-type mice were labeled with 5 μM and 0.5 μM CFSE 
(Molecular Probes) respectively, mixed (1:1), and injected i.v. into recipients (1-3 x 
106/mouse), followed 24 h later by mAb i.v.. 16 h later splenocytes were analyzed to 
determine target to non-target CFSE-labeled B cells ratio. To assess depletion of hCD20 
Tg x Vav-Bcl-2 B cells, hCD20 x Vav-Bcl-2 and hCD20 Tg splenocytes were labeled 
with 5 μM and 0.5 μM CFSE, respectively, and wild-type splenocytes with 20 μM 
PKH26 (Sigma), mixed (1:1:1), injected and treated with mAb as described above.  The 
ratio of both target B cell populations was compared with the PKH26 labeled non-target 
cells.  
 
Clinical Samples 
Ethical approval for the use of clinical samples was obtained by the Southampton 
University Hospitals NHS Trust from the Southampton and South West Hampshire 
Research Ethics Committee. Informed consent was provided in accordance with the 
Declaration of Helsinki. Samples were released from the Human Tissue Authority 
licensed University of Southampton, Cancer Science Division Tissue Bank. Samples were 
assessed as single cell suspensions that had been isolated, Ficoll purified and 
cryopreserved for subsequent analysis. 
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Western blotting 
Western blotting was performed as described previously 26. Briefly, 2.5-5 x 106 hCD20 Tg 
B cells were treated for 6 h in vitro with Alexa-488 mAb (10 μg/ml), washed and lysed in 
onyx buffer. Samples were then separated by SDS PAGE and proteins transferred 
immediately onto PVDF membrane. Membranes were blocked with 5% non-fat dried 
milk, incubated with the appropriately diluted primary antibodies, washed and then 
incubated with horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG (Sigma 
Aldrich) and visualized by enhanced chemiluminescence (ECL, GE Healthcare) and 
exposure to light-sensitive film (Hyperfilm ECL, GE Healthcare). 
 
Internalization assay and Alexa-488 labeling 
MAb were labeled with Alexa-488 according to the manufacturer’s instructions 
(Invitrogen). Samples were incubated with Alexa-488 labeled mAb (5 μg/ml), harvested 
after 2, 6 or 24 h, washed, resuspended and incubated at 4oC for 30 min in the presence or 
absence of anti-Alexa-488 quenching antibody (Invitrogen).  Samples were then assessed 
by flow cytometry. With human peripheral blood, B cells were identified by staining with 
RPE-labeled anti-CD19.  
 
PCR for CD20 mRNA 
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Purified B cells were treated as indicated and total RNA isolated, before conversion to 
cDNA (Invitrogen). PCR was performed using appropriate dilutions of cDNA and primers 
specific for human CD20 or mouse GAPDH as a control. 
 
Phagocytosis assay 
To generate bone marrow derived macrophages, adherent cells were isolated from the 
femurs of C57Bl/6 mice and cultured in vitro using L929 conditioned media for 5-8 days. 
On the day of the assay, macrophages were harvested using trypsin/EDTA (Invitrogen), 
resuspended in RPMI and plated into a 96-well tissue culture plate (5 x 104/well), and 
incubated for 2-4 h at 37°C.  Target B cells were prepared from spleens of hCD20 Tg 
mice and incubated for 16 h in the presence or absence of anti-CD20 mAb (10 μg/mL) to 
allow any modulation to take place, and then  labeled with 5 μM CFSE.  The cells which 
had not been treated with mAb were then labeled with anti-CD20 mAb for 30 min at 
room temperature to obtain the maximum level of surface binding.  The B cells were then 
added to the macrophages at a ratio of 5:1, the plates incubated for 30 min at 37oC then 
APC-anti-F4/80 antibody (AbDSerotec) added to distinguish the macrophages.  Cells 
were harvested and analyzed by flow cytometry. The percentage of cells that stained 
double positive for CFSE and APC-anti-F480, which includes macrophages with both 
surface bound and internalized B-cells, was determined as a measure of phagocytic 
potential. For qualitative evidence of phagocytosis macrophages were seeded into 
chambers slides (ibidi) with CFSE-labeled targets prepared as above. Following removal 
of unbound targets, slides were then imaged by confocal microscopy using LAS-AF v2 
software on a TCS-SP5 laser scanning confocal microscope (Leica Microsystems). 
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Fluorescence and Confocal Microscopy 
In vitro modulation 
Cells were incubated with Alexa-488 conjugated anti-CD20 mAb as required, and then 
50 nM Lysotracker Red DND-99 or 5 μg/ml Alexa-647 conjugated transferrin (both 
Invitrogen) were used for lysosome and endosome analysis respectively.  Cells were then 
transferred onto slides and images captured immediately using LAS-AF v2 software on a 
TCS-SP5 laser scanning confocal microscope (Leica Microsystems). 
In vivo modulation 
Mice were treated with Alexa-488 conjugated anti-CD20 (100 μg i.v.) for 24 h, then 
spleens were removed, paraformaldehyde fixed sections counterstained with TOPRO-3 
(Invitrogen), and imaged as above. 
 
Statistical analysis 
To compare differences between the experimental groups, a two-tailed t-test was 
performed using GraphPadPrism software. 
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Results 
 
Fc γ Receptor dependent depletion in human CD20 transgenic (hCD20 Tg) mice 
Type II (tositumomab-like) anti-CD20 mAb demonstrate significantly prolonged 
clearance of circulating B cells in congenic hCD20 Tg models when compared with their 
type I (rituximab-like) counterparts (1, 27 and Fig 1a). As a result of this enhanced 
potency, a single dose of 250 μg of type II mAb typically cleared circulating B cells for 
60 days, compared with 20-30 days for type I reagents.  Using an in vivo transfer model 
we also demonstrated enhanced splenic B-cell depletion by type II mAb (Fig. 1b). This 
depletion was dose dependent (Fig. 1c) and when comparing IgG2a isotype matched 
versions of rituximab (Rit m2a) and tositumomab, the latter was approximately 5 times 
more potent. Type I mAb have been variously proposed to engage complement 28, 29 and 
apoptotic cell death mechanisms 30, 31. To examine these different effector mechanisms, a 
series of transfer experiments was performed either with recipient mice lacking key 
effector molecules or with transferred cells from modified donors (Fig. 1d). In C1q -/- 
and C3-/- mice, the degree of B-cell depletion was equal to that in WT mice, suggesting 
no requirement for complement in this model1. When apoptosis-resistant (see 
Supplementary Fig. 1 and 32) double transgenic hCD20 x Vav Bcl-2 target cells were 
transferred, they were no less susceptible to depletion than normal hCD20 Tg targets with 
either type I or II mAb, indicating that induction of apoptosis is not a key effector 
mechanism in this model. In contrast, when engagement of mAb through FcγR was 
abrogated, either by transfer into γ-chain -/- mice or by utilizing F(ab’)2 fragments, B-cell 
depletion was completely curtailed (Fig. 1d, Supplementary Fig. 2) supporting a vital role 
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for FcγR dependent effector mechanisms3, 33, 34. Importantly, lack of activity with type II 
mAb in both FcγR-blunted models also indicates the lack of a role for the Fc independent 
non-apoptotic lysosome mediated cell death we have previously described6, 8, 35. Although 
seemingly at odds, these results can be reconciled by considering the different nature of 
the models used. Fc independent cell death can be demonstrated in a range of malignant 
B cells, with both cell lines and primary samples and, we would postulate, could be an 
important mechanism in this setting. However, we and others36 have been unable to 
demonstrate potent directly induced cell death in normal B cells in the absence of a 
mitogenic signal whether in human cells or hCD20 Tg mouse cells ex vivo or in vivo 
suggesting that this form of mAb-induced cell death may depend on cell cycling or prior 
triggering of the BCR. In this sense, the current observations regarding the depletion of 
normal B cells may have more relevance to the ever increasing use of anti-CD20 mAb in 
autoimmune conditions.  
 
Having demonstrated the importance of FcγR mechanisms in this model, we wanted to 
further elucidate the effector cells involved and utilized clodronate-containing liposomes 
to deplete the macrophage population24 in recipient mice. In line with previously 
published work37, 38 clodronate treated mice were unable to eliminate B cells, implicating 
macrophages as the most likely effectors (Fig. 1d, Supplementary Fig. 2). Finally, to 
determine whether the difference observed in potency between type I and II mAb could 
be explained by the so called ‘shaving’ phenomenon described by Taylor and 
colleagues39, where antibody:CD20 complexes are removed from the cell surface through 
engagement of CD64, we performed B-cell depletion in a) CD64-/- x hCD20 Tg mice 
 14
(not shown) and b) by transfer of hCD20 Tg B cells into wild type or CD64 -/- mice (Fig. 
1e) and found no significant effect on the potency of depletion by type I or II mAb. This 
would suggest that shaving does not play an important role in the in vivo difference 
between these mAb. These data demonstrate for the first time that both type I and II mAb 
utilize the same macrophage- and FcγR-dependent effector mechanism in vivo, and 
therefore differences in the mechanism of deletion cannot explain the superior potency of 
type II mAb. 
 
Rituximab rapidly modulates CD20 from the cell surface 
One indication of a critical difference between the activities of the two types of anti-
CD20 mAb came when CFSE-labeled hCD20 Tg B cells were transferred into γ-chain -/- 
mice. Here, the absence of activatory FcγR prevents deletion of target cells, permitting 
their study after mAb administration (Fig. 1d).  In these experiments CD20 levels were 
determined by incubating cells with an excess of each anti-CD20 mAb and the same anti-
mouse Fc specific PE- conjugated secondary antibody permitting a direct comparison of 
mAb binding levels with a common secondary reagent. In this system, treatment with 
type I mAb for 16 h evoked a reduction of approximately 80-90% in the level of CD20 
present on the surface of B-cells whereas type II mAb left CD20 largely unchanged (Fig. 
2a). This was confirmed in hCD20 Tg x γ -/- mice (Fig. 2b) where all normal B-cell 
subsets express hCD20, precluding anomalies within the adoptive transfer model being 
responsible for the differences. Type I mediated modulation of CD20 was dose dependent 
in vivo and required the continued presence of mAb (data not shown and Supplementary 
Fig. 3). Rapid modulation of CD20 also occurred on purified splenic B-cells in vitro with 
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type I but not type II mAb (Fig. 2c). These data, taken with the fact that modulation 
occurs in γ−chain -/- (activatory FcR negative) mice and with purified B cells illustrate 
that this process does not require FcR engagement by effector cells and therefore appears 
an intrinsic B-cell phenomenon separate from the CD20 shaving reaction40. In light of 
these findings we reassessed the potential of anti-CD20 mAb to mediate phagocytosis of 
B cells following overnight treatment with mAb and found that the drop in CD20 surface 
expression after Rit m2a treatment resulted in a 50% loss in the ability of macrophages to 
capture Ab-coated B cells (Fig. 2d), while B cells treated with tositumomab remained 
equally sensitive to macrophage attack.  These results clearly demonstrate that CD20 
modulation by type I mAb impairs their ability to engage critical FcR-dependent effector 
cells possibly explaining the reduced efficacy of type I mAb in B-cell depletion (Fig. 1a 
and 1). Although others have previously demonstrated modulation of CD20 from the cell 
surface as a direct result of mAb ligation21, 22 we believe this is the first study to 
demonstrate a potential therapeutic consequence of such B-cell intrinsic modulation. 
 
Rituximab is consumed in vivo 
In addition to reducing the efficiency of effector cell engagement, extensive modulation 
is also likely to perturb mAb half-life as a result of consumption and degradation by 
CD20+ B cells.  However, we had previously reported that both type I and II mAb half-
lives in depleting mice were largely equivalent based upon assays using radiolabelled 
mAb1. Given our new findings, we reassessed antibody half-life using a new highly 
sensitive flow cytometry based assay which, importantly, measures intact, bio-active 
mAb (capable of binding CD20+ cells) in the serum as opposed to measuring 
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radioactivity recovered from whole blood which could include degraded, inactive mAb or 
mAb internalized by cells giving falsely high readings for type I mAb. In contrast to our 
previous results, using this system and consistent with the suggestion that modulation 
will affect mAb consumption, we found that in wild-type mice the half-life of all the 
mAb was the same at 14 days, but in hCD20 Tg mice, the type I and II mAb persisted 
with half-lives of 6-7 and 14 days, respectively (Fig 3a and b centre panel).  Thus these 
results correspond with the extent and duration of B-cell depletion seen in Fig. 1 and 
demonstrate that the faster decay of type I mAb shown in hCD20 Tg mice is a function of 
binding to and consumption by CD20+ B cells. Moreover, in hCD20 Tg x γ-chain -/- 
mice (Fig 3b, right panel), where the anti-CD20 mAb bind to B cells that are not 
depleted, a similar or slightly accelerated, rate of type I mAb decay was observed, 
supporting the hypothesis that they are consumed by B cells in an active, antigen specific 
process which does not require effector cell interactions and excludes a role for shaving 
by activatory FcγR-expressing effectors. Further to the observed correlation of mAb half-
life and extent of depletion, peripheral B-cell repopulation correlated with the decline in 
serum mAb levels (Fig. 3c). When mice treated with either type I or II mAb received a 
repeat dose of the same mAb just as their B cells returned to the circulation (days 40 and 
90, respectively), they showed secondary depletion essentially the same as that after 
primary treatment (Supplementary Fig. 4). This suggests that B cells in type I mAb 
treated mice are not inherently refractory, but simply that the duration of depletion 
reflects the kinetics of mAb consumption.  In this regard we found that the reduced 
efficacy of type I mAb can, at least in part, be overcome by maintenance administration. 
Using a regimen of 25, 50 or 100 μg/week for 5 weeks, Rit m2a was maintained in the 
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serum at much higher levels (approximately 5, 12 and 40 μg/ml respectively at day 40, 
compared with 2 μg/ml with a single administration; Supplementary Fig. 5), leading to 
longer lasting depletion of B cells compared with a single dose. However, maintenance 
dosing, although improving the performance of Rit m2a, still could not equal the 
depleting efficacy of a single dose of the type II mAb tositumomab at equivalent doses 
(Fig. 3d).   
 
Modulated rituximab is internalized not shaved 
Although using secondary antibodies to detect surface bound mAb is able to provide a 
measure of the surface expression level of CD20, it does not permit the study of the fate 
of the anti-CD20 mAb. To investigate this more fully we used a method adapted from the 
surface fluorescence-quenching method of Austin et al41, after comparing these 
techniques to ensure that they gave similar results (Supplementary Fig. 6). This 
fluorescence quenching technique permitted us to determine simultaneously the extent of 
modulation and whether the modulated mAb were internalizing. Firstly we compared 
whether fluorescently labeled Rit m2a (Rit-488) or tositumomab (Tosit-488) internalized 
with CD20 as it modulated from the cell surface. We found that when administered to 
cells in vitro (Fig. 4a) or in vivo (Fig. 4b), Rit-488 but not Tosit-488 was rapidly 
internalized as detected by its inaccessibility to surface quenching. Further, splenic B 
cells from Rit-488 treated mice accumulated appreciable levels of intracellular 
fluorescence, in marked contrast to results with Tosit-488 (Fig. 4b and 4c left panel). This 
accumulation resulted in B cells becoming approximately 4 times more strongly stained 
with Rit-488 than Tosit-488 (Fig. 4b upper panel). Moreover, the Rit-488 was localized 
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predominately inside the cells, with little remaining on the surface, whilst the Tosit-488 
remained almost exclusively on the cell surface (Fig. 4c lower panel). Internalization 
correlated with a localized punctate staining pattern, which was also observed in spleen 
sections after in vivo administration of Rit-488 but not Tosit-488 (Fig. 4c and 
Supplementary Movie 1). Importantly, type I mAb mediated internalization occurs in 
wild type FcγR expressing hCD20 Tg mice (data not shown) indicating that it occurs in 
vivo during B-cell depletion. This internalization is an active process requiring 
permissive temperature, energy production and actin cytoskeletal rearrangements (Fig. 
4d). Furthermore, treatment with Rit m2a but not tositumomab leads to a reduction in the 
total levels of CD20 protein and a concomitant degradation of internalized mAb as 
detected by the loss of IgG-Alexa488 conjugate (Fig. 4e). CD20 mRNA levels remain 
relatively constant throughout, suggesting that the cells are unable, at least in the short 
term, to upregulate CD20 in response to these events (Fig. 4f). Taken together these data 
provide an explanation for the consumption of rituximab in vivo, the kinetics of its decay 
in the serum and the concordant recovery of B-cell numbers.  
 
CD20 mAb rapidly internalize and are targeted to the lysosome in normal human B 
cells and CLL 
Having established the rapid and extensive internalization of type I mAb with hCD20 Tg 
B cells we sought to clarify whether this was an artifact of this Tg model . Although there 
have been previous reports demonstrating CD20 internalization with mAb ligation21, 22 
the majority of studies have shown that CD20 does not modulate42, 43.  Indeed, the first 
clinical use of anti-CD20 mAb, 1F5, by Press and colleagues showed that mAb did not 
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undergo antigenic modulation from patient tumor cells and this was highlighted as a 
benefit of such a reagent44. Furthermore, we have reported that CD20 did not 
substantially modulate from Raji BL cells or a primary CLL sample in a short-term two 
hour culture45. In order to clarify these apparent discrepancies we determined to study 
modulation on a variety of B cell targets. Michel and Mattes have previously 
demonstrated the internalization of CD20 on certain human B-cell lines following mAb 
engagement but found it to be slow with little internalization until 18 hours22. We found 
very similar results in our experiments where internalization of CD20 occurred in a panel 
of 8 human B-cell lines in vitro following Rituximab-488 (Ritux-488) but not Tosit-488 
treatment (Fig. 5a), again with internal punctate staining (Fig. 5b), albeit considerably 
less rapidly than in the hCD20 Tg mouse B cells. Using these cell lines we were able to 
confirm22 the trafficking of type I CD20 mAb to early endosomes and lysosomes as 
detected by fluorescent transferrin and LysotrackerTM, respectively (Fig. 5c) illustrating 
the route of CD20:type I mAb complex internalization and degradation. In sharp contrast, 
modulation and internalization of CD20:type I mAb occurred much more rapidly in 
normal human peripheral blood B cells (Fig. 6a) being comparable with that seen in the 
hCD20 Tg mouse model (Figure 3a). We next examined a panel of primary tumors and 
revealed marked heterogeneity in the rate of Ritux-488 CD20 internalization. As shown 
in Figure 6b, CLL cells demonstrated the most rapid kinetics and internalization levels 
followed by MCL, then FL and finally DLBCL cells, which displayed very little 
internalization out to 24 hours of culture (Fig. 6b and data not shown). For CLL, there 
was considerable variation in the rate of modulation, with internalization rates straddling 
that seen in normal B cells.  In contrast, FL and DLBCL were generally much slower to 
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internalize than CLL (p<0.05 at 6h) with the exception of two outlier FL samples which 
displayed atypical rapid internalization. This heterogeneity, especially if studying small 
patient cohorts with mixed tumor types, might help explain some of the confusion as to 
the tendency of CD20 to be lost from tumor cells.  The data also offers the intriguing 
possibility that modulation of CD20 by type I mAb might be a useful predictor of 
therapeutic outcome.  For example, it could help explain why SLL, and CLL, which as a 
rule respond relatively poorly to rituximab, also consume mAb in larger amounts than 
equivalent cases of FL 46, 47.  We are currently exploring the mechanisms underlying 
these differences.  Furthermore, the outlier cases of FL which modulate rapidly provide 
an ideal opportunity to investigate pheno- or geno-typic differences that might control 
CD20 modulation.  However, irrespective of the molecular explanation, the modulation 
and consumption of type I of anti-CD20 mAb has clear implications for the use of 
rituximab or non-modulating type II reagents in malignant and autoimmune settings. 
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Discussion 
 
Anti-CD20 immunotherapy is rapidly evolving, with multiple new mAb designed to 
harness different effector pathways now in clinical trials 2. The diversity of the mAb 
being tested reflects the uncertainty regarding the critical mechanism of action for these 
reagents and which effector pathways should be harnessed for optimal efficacy.   
 
This study demonstrates for the first time that the same Fc:FcγR dependent mechanism is 
critical for the in vivo activity of both type I and type II reagents. Despite this common 
mode of action it is clear that type II mAb produce more effective B-cell depletion. The 
approximately 5-fold enhanced efficacy of tositumomab shown here was independent of 
complement activity or direct induction of apoptosis. Although we cannot entirely rule 
out the possibility that type II mAb achieve this efficacy in part through the induction of a 
non-apoptotic cell death pathway, such as described for NHL cell-lines 6, 8, 35, we have so 
far been unable to demonstrate this on isolated hCD20 Tg B-cells (data not shown). 
Furthermore, cell death through this route does not require additional cross-linking or Fc 
presence 6, 8, 35 and given the lack of depletion in γ-chain -/- mice and with F(ab’)2 
fragments, it seems unlikely that direct induction of non-apoptotic cell death plays a 
major role in this model. However, presumably in NHL, both mechanisms will 
potentially operate to further improve the efficacy of type II vs type I anti-CD20 mAb 
 
The enhanced ability of type II reagents to deplete B cells appears to be related to the fact 
that they elicit little modulation of CD20 from the cell surface. In contrast, the binding of 
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type I mAb induces a profound modulation of CD20, resulting in two concomitant 
effects; a reduction in effector cell mediated clearance of B-cells and enhanced mAb 
consumption. 
  
The literature on CD20 modulation is conflicting, with some reports suggesting that it 
occurs 21, 22, 48, while others have reported that it does not 42, 43, 49. These discrepancies 
may reflect the cell types and different mAb used. In many cases heavily-passaged B-cell 
lines and xenograft models failed to show significant internalization unless incubated 
with type I mAb over a long period (e.g. 18-24 h).  In contrast, here, human B cells taken 
from the blood of healthy volunteers underwent internalization with similar kinetics to 
hCD20 Tg B-cells, within just 2 h.  The reasons underlying these differences in kinetics 
is currently under investigation. 
 
Variable resistance to depletion in vivo may also reflect how long the B cells are coated 
with type I anti-CD20 mAb and allowed to modulate before they encounter FcγR-
expressing effectors. As such, the length of time prior to encountering tissue resident 
effector cells or release into the circulation to gain access to the RE could explain the 
differential sensitivity of B cells in the periphery (most sensitive), bone marrow, and 
spleen (least sensitive). 
 
It is also possible that internalization may explain the differing sensitivity of B-cell 
malignancies to rituxumab. We have shown in a cohort of 26 CLL samples treated ex 
vivo that samples display a range of internalization rates, with some markedly enhanced 
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compared with normal B cells. This may predict defective cellular clearance and 
consumption of large quantities of mAb, as is observed clinically. Furthermore, this wide 
heterogeneity in modulation rate is likely to explain why we previously concluded that 
rituximab did not modulate rapidly from the cell surface based upon a far smaller cohort 
of CLL samples and BL cell lines45. Interestingly, while we see some CLL cases which 
modulate rapidly, for example up to 80 % loss of CD20 at 6 h, we do not see the almost 
complete loss reported by Jilani et al 21 after only 1-2 h, which possibly reflects 
differences in methodology. Interestingly MCL samples also modulated rituximab quite 
rapidly, in keeping with the relatively poor response of these lymphomas to rituximab 
treatment.  Conversely, FL and DLBCL samples in general demonstrate significantly 
slower internalization, corresponding with their greater sensitivity to rituximab and 
consistent with the literature in the field that CD20 is not lost from the cell surface during 
rituximab treatment. The molecular basis underlying the more rapid internalization seen 
in 20% of the FL samples is particularly intriguing and currently under study. 
Intriguingly, polymorphisms in FcγRIIIa have been found to correlate with clinical 
responses to rituximab with FL 50, 51 but not CLL 52. It is tempting to speculate that these 
associations are related to the rate of modulation observed in each disease, with the rapid 
modulation observed in CLL potentially negating the enhanced potency of the high 
affinity FcγRIIIa allele. 
 
Importantly, the deficiencies of rituximab due to mAb consumption could be largely 
overcome by maintenance treatment, suggesting that the reduced level of anti-CD20 mAb 
bound to ‘modulated’ targets is still sufficient (albeit not optimal) to trigger deletion by 
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effectors. However, this compensation was less apparent in the tissues where 
maintenance Rit m2a, although improved, was no more effective than a single dose of 
tositumomab, even when serum mAb levels were higher. Furthermore, our experiments 
demonstrate that FcR-dependent CD20 shaving does not play an important role in 
limiting the efficacy of Rit m2a in the current model, since depletion efficacy was dose-
dependent and low repeated doses of Rit m2a, as suggested by Taylor et al 39, did not 
improve performance. It is important to point out however that shaving may only occur 
when the RE phagocytic systems such as those of the liver become fully saturated, which 
may not occur when depleting B cells as opposed to large numbers of tumor cells. 
 
The data presented here suggest that type II mAb may be the most effective in depleting 
large numbers of B cells as in CLL. Type II mAb are essentially non-modulatory, are not 
rapidly consumed and maintain their ability to engage FcR-expressing effectors, avoiding 
the need for multiple dosing regimes and reducing the overall amount of mAb required. 
An alternative strategy, given the current clinical penetrance of type I mAb, would be to 
enhance their efficacy by blocking CD20 internalization following treatment, for example 
by interfering with the membrane fluidity 53, energy production or the actin machinery of 
the target cells.  Indeed, it is possible that cytotoxic agents act in this way by directly or 
indirectly affecting such pathways, perhaps helping to explain the efficacy of rituximab 
in combination with chemo- and radio-therapy. 
 
Recent clinical trials have assessed the efficacy of another type I mAb (ofatumumab) 16-18 
with improved affinity and CDC activity in CLL 9, 29. Interestingly, our preliminary 
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analysis (data not shown) indicates that this mAb, in keeping with its type I nature, will 
also suffer from rapid modulation, although its higher affinity and lower off-rate may 
provide greater activity at lower mAb serum levels. 
 
In summary, these results suggest that type II anti-CD20 mAb have considerable 
therapeutic potential in the treatment of B-cell diseases.  Until very recently tositumomab 
was the only type II mAb to have been investigated clinically and this almost exclusively 
as a radioimmunoconjugate. The second type II reagent, GA101, is currently undergoing 
clinical trials, with promising effects seen in both CLL and rituximab-treated FL 54 
Importantly, our data suggest an overlooked mechanism for resistance to anti-CD20 
mAb. The relevance of this to other target antigens and mAb is unknown but this study 
highlights the importance of fine specificity in regulating mAb effector functions 7, and 
suggests that internalization and consumption may be important criteria for selecting 
therapeutic mAb. Knowledge of the central pathways involved in modulation should 
allow the design of rational combination therapies to augment the effect of existing mAb 
treatments. 
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Figure Legends 
 
Figure 1. Type II anti-CD20 mAb deplete B-cells more effectively than type I mAb 
via a complement and apoptosis-independent mechanism that requires Fc:FcR 
engagement. a) Systemic depletion: hCD20 Tg mice (BALB/c background) received 250 
μg anti-CD20 mAb or isotype matched control i.v. on day 0 and the number of circulating 
B-cells assessed. Points show means, n ≥ 4 mice for each time point from 2-4 
independent experiments. b) Adoptive transfer:  hCD20 Tg target (T) or WT non-target 
(NT) BALB/c splenocytes labeled with high or low CFSE, respectively were injected i.v. 
into BALB/c mice. 24 h later mice received mAb (1 μg, i.v.) and 16 h later spleens 
analyzed to determine the T:NT ratio. Left panel: bars represent mean +/- s.d., n = 3-5 
mice for each treatment group.  * both type II mAb significantly differ from both type I 
mAb: Rit m2a vs FGM6, p< 0.02; Rit m2a vs Tosit p < 0.002; 1F5 vs FGM6 and 1F5 vs 
Tosit, p< 0.005.  Right panel: typical dot-plot data. c) Dose response to Rit m2a and 
tositumomab (Tosit) in a similar adoptive transfer: bars represent mean and range, n = 2 
mice at each concentration.  d) Contribution of effector mechanisms:  Ctl, transfer of T 
and NT into WT recipients as above; CDC,  NT and T cells transferred into complement-
deficient (C1q-/- and C3-/-) mice;  PCD,  hCD20 Tg and hCD20 x Vav-Bcl-2 double Tg 
(both T), and WT  (NT) labeled with high CFSE, low CFSE and PKH26 respectively 
transferred into WT mice and the level of both T compared with the NT; Fc:FcγR, T and 
NT cells transferred into γ-/- or  clodronate-treated (Clod) WT mice; also shown is the 
activity of F(ab’)2 fragments in WT recipients. Bars represent mean +/- s.d., n = 3 mice 
for each treatment group; each condition is representative of at least 2 independent 
experiments. e) Poor type I depletion is not due to shaving: Transfer of T and NT cells 
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into WT and CD64 -/- mice as described above with Ctl, Rit m2a or Tosit mAb. Bars 
represent mean and range, n = 2 mice for each treatment group; representative of at least 
2 independent experiments.   
 
Figure 2. Type I mAb treatment results in modulation of CD20 from the cell surface 
both in vivo and in vitro. a) hCD20 Tg B cells transferred into non-depleting γ -/- mice 
as in Fig. 1c were assessed 16 h after mAb treatment for CD20 surface expression by 
detecting bound mAb with PE-labeled anti-mouse Fc. Red, Rit m2a; blue, tositumomab; 
solid, background. Top histogram, CD20 expression on B cells from untreated mice 
labeled with Rit m2a and tositumomab ex-vivo; bottom histogram, CD20 expression after 
treatment with Rit m2a or tositumomab in-vivo.  Bar chart; CD20 expression after 
treatment with type I and type II mAb; bars represent mean +/- s.d., n ≥ 3mice, one of at 
least 3 experiments. * Rit m2a and 1F5 significantly differ from FGM6 and tositumomab, 
p< 0.0001. b) Surface CD20 expression on peripheral B-cells in hCD20 Tg γ−chain -/- 
mice after mAb treatment (250 μg); red, Rit m2a; blue, tositumomab; solid, background; 
black, untreated. c) Loss of surface CD20 in vitro. Isolated splenic hCD20 Tg B Cells 
were incubated with Rit m2a or tositumomab (10 μg/ml) before detecting surface CD20. 
Bars represent mean and range for 2 experiments each performed in triplicate. d) 
Phagocytic potential is reduced by treatment of CD20 Tg B-cells with Rit m2a.  Cells 
were treated for 16 h with mAb, labeled with CFSE, incubated with bone marrow-derived 
macrophages, and then APC-F4/80 labeled before flow cytometry to detect double +ve 
macrophages (left hand panel) or confocal microscopy (right hand panel). As shown in 
c), 16 h  incubation with Rit m2a but not tositumomab caused loss of CD20 and resulted 
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in a reduction in the number of double +ve macrophages (*,  p< 0.0001). Bars represent 
mean +/- s.e.m. of triplicate samples, one of 3 similar experiments.  Right hand panel 
shows a typical image of macrophages capturing and engulfing CFSE-labeled B-cells 
coated with tositumomab. 
Figure 3. Serum mAb levels correlate with B-cell depletion kinetics. a) and b) WT, 
hCD20 Tg, and CD20 Tg γ-chain -/- mice were treated with mAb (250 μg), and the serum 
mAb concentration measured after 1, 7 and 28 days by incubating sera with SU-DHL-4 
cells and then detecting cell-bound mAb with FITC-labeled anti-mouse Fc, and 
comparing the level with a standard curve. a) shows representative histograms; solid 
histogram, background staining; blue, type II mAb tositumomab; red and green, type I 
mAb Rit m2a and 1F5, respectively. b) shows the concentration of mAb in the serum.  n 
= 3 mice per group, bars show mean +/- s.d.  c) Correlation of serum mAb levels and B-
cell repopulation in the periphery. hCD20 Tg mice were treated with a single dose of 
mAb (250 μg) and the mAb level in the serum and B cell numbers assessed. Bars show 
mean +/- s.d., n = 3 mice per group. d) Repeated low level dosing (25, 50 or 100 μg 
weekly for 5 weeks) with Rit m2a potentiates B-cell depletion compared to a single large 
dose (250 μg) of mAb to a level equivalent to that seen with tositumomab. The level of 
B-cells in the blood and secondary lymphoid organs was assessed on day 40 by flow 
cytometry and IHC staining for T (blue) and B (yellow) cells. Serum mAb levels were 
also assessed (Supplementary Figure 5) with repeated doses shown to enhance mAb 
serum levels. 
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Figure 4. Type I mAb modulate CD20 from the cell surface through internalization, 
leading to mAb and CD20 degradation. a) hCD20 Tg B cells were incubated in vitro 
with Rit m2a-Alexa488 (Rit-488) or Tosit-Alexa488 (Tosit-488) mAb  (5 μg/ml) for 1, 2 
or 6 h, washed,   then incubated in the presence or absence of  anti-Alexa488 quenching 
Ab. The fluorescence remaining after quenching indicates the proportion of internalized 
mAb (histogram upper panel). Bars represent mean with range for duplicate 
determinations, one of three similar experiments. b) hCD20 Tg x γ -/- mice were 
administered Rit-488 or Tosit-488 (100 μg) i.v. and the amount of fluorescence 
associated with splenic B cells was assessed 24 h later (upper panel), Rit-488 treated B 
cells accumulated approximately 4 x the fluorescence compared with that of Tosit-488 
treated mice (n=3 mice). Despite the Rit m2a treated B cells having a higher level of B-
cell associated fluorescence, the Tosit treated  B cells (blue) expressed more CD20 on 
their surface than Rit-488 treated cells (red)(lower panel), histograms from one of three 
similar experiments. c) Left panel, in vivo treatment: 10 μm spleen sections from mice 
treated as in b) were analyzed by confocal microscopy.  Assessed at the same gain 
intensity, far greater mAb accumulation is evident after Rit m2a (upper panels), with its 
more punctate staining apparent when Rit m2a and Tosit were compared at optimized 
gain intensity (lower panels). Right panel, in vitro treatment: hCD20 Tg B-cells treated 
with Rit-488 (5 μg/ml) in vitro and assessed by confocal microscopy with a maximal 
projection, Z section through the centre of the cell and overlaid versus the bright field 
(Bf). d) Internalization of Rit-488 or Tosit-488 on hCD20 Tg B cells under normal 
conditions (NT), at 4oC, in the presence of azide (Azd, 15 mM) or latrunculin B (Lat B, 
50 μM). Bars represent mean with range for duplicate determinations, one of three similar 
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experiments. e) hCD20 Tg B cells treated with Rit-488 or Tosit-488 for 6 h and assessed 
by western blot for the expression of intact Alexa488- IgG, CD20 and actin (as a loading 
control). f) mRNA levels of CD20 and GAPDH (as a control) were assessed in the same 
cells. 
 
Figure 5. Type I mAb internalize in human cell-lines and traffic to the lysosome. a) 
A selection of NHL cell-lines (Raji, Daudi, SUDHL4, DOHH2, Ramos, Granta-519, RL, 
HBL-1) were treated with Rituximab-Alexa488 (Ritux-488) or Tosit-488 (5 μg/ml) for 2, 
6 or 24 h and then assessed for internalization as before. At each time point, the level of 
surface accessible CD20 with Ritux-488 was significantly lower than with Tosit-488; 2 h, 
p<0.001, 6 and 24 h, p<0.0001. b) Appearance of Raji B cells treated with Ritux-488 or 
Tosit-488 (5 μg/ml) for 24 h in vitro and assessed by confocal microscopy with a Z 
section through the centre of the cell and overlaid versus the bright field (Bf). c) Co-
localisation of Ritux-488 with transferrin-647 or Lysostracker™ on Raji cells.  
 
Figure 6. Type I mAb internalize in primary normal and malignant human B-cells. 
a) Normal human peripheral blood B-cells were isolated by negative selection, treated 
with Ritux-488 or Tosit-488, (5 μg/ml) for 2, 6 or 24 h and then assessed for 
internalization as before. Results from 8 different donors are shown.  At each time point, 
the level of surface accessible CD20 with Ritux-488 was significantly lower than with 
Tosit-488, p<0.0001. b) CLL, MCL, FL or DLBCL samples were treated with Ritux-488 
or Tosit-488 (5 μg/ml) for 2 or 6 h and then assessed for internalization as before. The 
amount of surface accessible CD20 after Ritux-488 was significantly lower than after 
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Tosit-488 at 6 h for CLL, MCL and FL; p<0.0001; p < 0.0013; and p < 0.006,  
respectively.  The table shows the significance of the difference in the rate of 
internalization of Ritux-488 between CLL and other disease subtypes. Each data point 
represents a sample from a different patient; CLL n = 26, MCL n = 5, FL n = 9 and 
DLBCL n = 5.  
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